Hoffmann-La Roche: Geographic Atrophy trials

The registry lists 16 Geographic Atrophy studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 7Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruitingNCT07851259Phase 2
• A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251RecruitingNCT05626114Phase 2
• A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT04607148Phase 2Results posted
• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)TerminatedNCT03972709Phase 2Results posted
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)TerminatedNCT02745119Phase 3Results posted
• A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic AtrophyCompletedNCT02288559Phase 2Results posted
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02247531Phase 3Results posted
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02247479Phase 3Results posted
• An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic AtrophyTerminatedNCT01602120Phase 2Results posted
• A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT06961370Phase 1
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationCompletedNCT04615325Phase 1
• Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT03295877Phase 1
• A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02479386
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02399072
• A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic AtrophyCompletedNCT01229215Phase 2
• A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic AtrophyCompletedNCT00973011Phase 1